DRP: Developmental Research Program

项目摘要--发展研究方案(DRP) UPMC Hillman癌症中心卵巢癌发展研究计划(DRP) 孢子寻求为卵巢癌的翻译驱动的创新试点项目提供资金和便利。这个 首要目标是通过刺激新的研究来降低卵巢癌的发病率和死亡率 预防和早期检测领域；肿瘤发生机制和治疗耐药；预测性 和预后生物标记物；以及治疗的新靶点和方法。DRP的另一个目标是 在卵巢癌研究中建立对代表不足的少数群体的支持。为了实现这些目标，DRP 将建立在通过之前的联合P50奖开发的成功计划和基础设施的基础上，该奖项导致 大约35倍的投资回报。DRP将每年广泛征求建议书，使用当地和 国家网络。为了更多地招募代表不足的少数族裔加入我们的DRP计划，DRP将 利用匹兹堡大学和HCC与少数族裔服务机构的计划来增加 代表人数不足的科学家的参与。此外，内部和外部咨询委员会成员 将鼓励董事会确定可以为DRP的多样性做出贡献的调查人员。最多的 将根据NIH式的两级审查选出有价值的提案，以确保严谨和不存在 偏见。DRP联席董事、孢子执行委员会、患者权益倡导者和孢子调查员将 参与第一级科学审查，必要时与特别审查人员一起参与。最终的选择 获奖者名单将在涉及孢子内部咨询的第二级方案审查之后作出 冲浪板。每个奖项将提供5万美元的资金，其中一半来自DRP，另一半来自DRP 其中一半来自CC，表明了实质性的机构承诺。DRP每年将资助三名飞行员， 保留一个给代表不足的少数族裔调查员。DRP奖获得者将是卵巢癌的新手 指派了一位经验丰富的导师来指导和融入孢子。获奖者将是 提供对肝细胞癌卵巢癌孢子核心资源的全面访问，包括组织标本和 生物信息学/生物统计学支持，不仅是为了确保项目成功，也是为了支持后续供资 在孢子机制之外的应用。所有DRP获奖者将每两年与DRP Co- 董事，每年准备进度报告，并在孢子会议上做研究报告。那些 这表明，重大研究进展将有资格获得第二年的竞争性续签。 有可能产生重大翻译影响的特殊飞行员可以提升到完整的孢子项目。这个 DRP为实现孢子发育不同卵巢池的目标提供了重要的机制 癌症研究人员致力于克服这种致命的疾病。

PROJECT SUMMARY – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The Developmental Research Program (DRP) of the UPMC Hillman Cancer Center (HCC) Ovarian Cancer SPORE seeks to fund and facilitate translationally-driven, innovative pilot projects in ovarian cancer. The overarching goal is to decrease ovarian cancer morbidity and mortality through stimulating new research in the areas of prevention and early detection; mechanisms of tumorigenesis and therapeutic resistance; predictive and prognostic biomarkers; and novel targets and approaches to therapy. An additional goal of the DRP is to establish support for underrepresented minorities in ovarian cancer research. To accomplish these goals, DRP will build on the successful program and infrastructure developed via a previous joint P50 award that resulted in an approximate 35-fold return on investment. The DRP will widely solicit proposals annually using local and national networks. To increase recruitment of underrepresented minorities to our DRP program, DRP will leverage University of Pittsburgh and HCC programs with Minority Serving Institutions to increase the participation of under-represented scientists. Additionally, members of the Internal and External Advisory Boards will be encouraged to identify investigators who could contribute to the diversity of the DRP. The most meritorious proposals will be selected based on an NIH-style two-tiered review to ensure rigor and absence of bias. The DRP Co-Directors, SPORE Executive Committee, Patient Advocates, and SPORE investigators will participate in the first-tier scientific review, together with ad hoc revewers when necessary. The final selection of awardees will be made following a second-tier programmatic review involving the SPORE Internal Advisory Board. Each award will provide $50,000 in funds, with half of the monies coming from the DRP and the other half from HCC, demonstrating substantial institutional commitment. DRP will fund three pilots per year, reserving one for an underrepresented minority investigator. DRP awardees new to ovarian cancer will be assigned an experienced mentor to provide guidance and integration into the SPORE. Awardees will be provided full access to the HCC Ovarian Cancer SPORE Core resources, including tissue specimens and bioinformatic/biostatistical support, not only to ensure project success but also to support subsequent funding applications outside the SPORE mechanism. All DRP awardees will meet bi-annually with the DRP Co- Directors, prepare progress reports annually, and make research presentations at SPORE meetings. Those that demonstrate significant research progress will be eligible for competitive renewal for a second year. Exceptional pilots with potential for significant translational impact can be elevated to full SPORE projects. The DRP provides a vital mechanism for achieving the SPORE’s goal of developing a diverse pool of ovarian cancer researchers committed to overcoming this deadly disease.